Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, FDA

Occlutech's Atrial Flow Regulator (AFR) Receives U.S. FDA Breakthrough Device Designation


SCHAFFHAUSEN, Switzerland, Dec. 18, 2020 /CNW/ -- Occlutech, a privately-held company, announced today that the US Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its first-in-class, implantable Atrial Flow Regulator (AFR) for Pulmonary Arterial Hypertension (PAH).

PAH affects hundreds of thousands in the U.S. and globally and is resulting from changes in cells that causes damages of the lung arteries. Consequentially, the heart is forced to work harder to supply enough oxygen. The patient experiences symptoms such as shortness of breath, dizziness and fatigue. The severity of these symptoms usually correlates with progression of the disease and significantly reduced quality of life. Over time, the right ventricle enlarges to hold more blood and the additional strain gradually causes the heart to fail. By placing the Occlutech AFR device into the septum and creating a restrictive atrial septal opening by maintaining the correct sizing of a created shunt, the intra cardiac pressure is substantially reduced, thereby improving the heart's function.

Breakthrough Device Designations are aimed to accelerate the development, assessment, and approval of new treatments in severe diseases, including a prioritized review all the way through market approval.

"It is an important milestone for us to have received this breakthrough designation," says Sabine Bois, Co-CEO Occlutech Group. "We are very proud and excited to work closely with the FDA in this opportunity to develop an important new therapy that positively impacts the lives' of critically ill patients."

Occlutech is one of the leading companies in its field, with several major products including state-of-the-art PFO occluders, ASD occluders among others. Occlutech has sales of congenital and structural heart products in over 80 countries and maintains manufacturing and R&D facilities in Jena, Germany and Istanbul, Turkey. Occlutech has developed many novel products and technologies to improve treatment of patients in these and related areas.

For additional information about the Company's products, the Occlutech AFR, or to inquire about participation in our patient registries, please visit Occlutech's website at www.occlutech.com, or contact us directly at [email protected].

The AFR is not approved in the United States. Product availability is subject to local regulatory clearance. The AFR is under clinical investigation for use in patients with pulmonary arterial hypertension and use in these patients is limited by applicable national laws.

Contact:
Sabine Bois                                                                                                               
Co-CEO Occlutech Group                                                                    
Mobile: +49 160 90792130                                                                                      
Email: [email protected]                                                                     

 

SOURCE Occlutech International


These press releases may also interest you

at 11:40
BiaTech Corporation today announced it has joined NVIDIA Inception, a program that nurtures startups revolutionizing industries with technological advancements. BiaTech is focused on AI-enabled edge and cloud technology for clean energy and utility...

at 11:32
Demandbase, the leader in AI-driven account-based go-to-market (GTM), today announced that it has not only been recognized as a leader in numerous G2 Spring Reports, it has also achieved a highly coveted placement on G2's Best Marketing & Digital...

at 11:25
The "Consumer Brain-Computer Interface: Market and Product Development Trends" report has been added to ResearchAndMarkets.com's offering. Over the past decade, brain-computer interface (BCI) technology has expanded beyond the confines of the...

at 11:25
Caravelle International Group , a global ocean technology company, today announced that it received a notice from The Nasdaq Stock Market LLC indicating that, as a result of not having timely filed its Annual Report on Form 20-F for the fiscal year...

at 11:19
On 29 March 2024, BTR New Material Group Co., Ltd. ("BTR")(835185.BJ), a global leader in battery materials, inked an investment agreement with the Moroccan government to erect a lithium battery ternary cathode material facility in the country. The...

at 11:13
Leading diagnostic and therapeutic medical technology company Laborie Medical Technologies Corp. (Laborie)?announced its investment in iO Urology, a venture-backed medical technology company that developed CarePath® an at-home, handheld uroflow...



News published on and distributed by: